GZMB and COVID-19: Moreover, NK cells from COVID-19 patients exhibited increased Granzyme B expression, with CD56bright NK cells showing a median of 87.41% (IQR: 82.78-92.34, P<0.0001), which was 10% higher than that observed in Control-LS individuals.